Age Related Macular Degeneration - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 252 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Age Related Macular Degeneration - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Age Related Macular Degeneration - Pipeline Review, H2 2014', provides an overview of the Age Related Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Age Related Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Age Related Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Age Related Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Age Related Macular Degeneration Overview 11
Therapeutics Development 12
Pipeline Products for Age Related Macular Degeneration - Overview 12
Pipeline Products for Age Related Macular Degeneration - Comparative Analysis 13
Age Related Macular Degeneration - Therapeutics under Development by Companies 14
Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 20
Age Related Macular Degeneration - Pipeline Products Glance 22
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Age Related Macular Degeneration - Products under Development by Companies 25
Age Related Macular Degeneration - Products under Investigation by Universities/Institutes 30
Age Related Macular Degeneration - Companies Involved in Therapeutics Development 31
Advanced Cell Technology, Inc. 31
Alcon, Inc. 32
Alkeus Pharmaceuticals, Inc. 33
Allergan, Inc. 34
AlphaMab Co., Ltd 35
Amarna Therapeutics B.V. 36
AngioGenex, Inc. 37
Angstrom Pharmaceuticals, Inc. 38
Aprogen, Inc. 39
Auven Therapeutics Management L.L.L.P 40
BioDiem Ltd 41
BioMAS Ltd. 42
Cellceutix Corporation 43
Clanotech AB 44
Digna Biotech, S.L. 45
Dong-A Socio Group 46
e-Therapeutics plc 47
Eucalyptus Ltd. 48
F. Hoffmann-La Roche Ltd. 49
Gene Signal International SA 50
Genzyme Corporation 51
Grupo Ferrer Internacional, S.A. 52
HanAll Biopharma Co., Ltd. 53
Huabo Biopharm Co., Ltd. 54
Innovent Biologics, Inc. 55
Intellect Neurosciences, Inc. 56
Jeil Pharmaceutical Co., Ltd. 57
Johnson & Johnson 58
Lead Discovery Center GmbH 59
LeadArtis S.L. 60
Mabion SA 61
Merz Pharma GmbH & Co. KgaA 62
Navigen Pharmaceuticals, Inc. 63
NeoStem, Inc. 64
Neovacs SA 65
Neumedicines Inc. 66
Neuroptis Biotech 67
OcuCure Therapeutics, Inc. 68
Omeros Corporation 69
Ora Bio Ltd. 70
Orphagen Pharmaceuticals, Inc. 71
Promedior, Inc. 72
R-Tech Ueno, Ltd. 73
RestorGenex Corporation 74
SelectX Pharmaceuticals, Inc. 75
Shionogi & Co., Ltd. 76
Sirnaomics, Inc. 77
StemCells, Inc. 78
Sumitomo Dainippon Pharma Co., Ltd. 79
Valens Therapeutics, Inc. 80
Varinel, Inc. 81
Wellstat Ophthalmics Corporation 82
X-BODY BioSciences, Inc. 83
Age Related Macular Degeneration - Therapeutics Assessment 84
Assessment by Monotherapy Products 84
Assessment by Target 85
Assessment by Mechanism of Action 88
Assessment by Route of Administration 90
Assessment by Molecule Type 92
Drug Profiles 94
A-6 - Drug Profile 94
AD-4 - Drug Profile 96
aganirsen - Drug Profile 97
AGX-51 SR - Drug Profile 99
Antibody for Age Related Macular Degeneration - Drug Profile 100
AP-202 - Drug Profile 101
AS-101 - Drug Profile 102
AVT-101 - Drug Profile 104
BDM-E - Drug Profile 105
brimonidine tartrate implant - Drug Profile 107
Carboxyamidotriazole Orotate - Drug Profile 109
CIGB-166 - Drug Profile 110
CLG-561 - Drug Profile 111
CLT-28643 - Drug Profile 112
CNTO-2476 - Drug Profile 113
DA-3131 - Drug Profile 114
disitertide - Drug Profile 115
Drug for Age Related Macular Degeneration - Drug Profile 117
Drug to Inhibit Tyrosine Kinase for AMD - Drug Profile 118
Drugs to Inhibit Tyrosine Kinase for Ophthalmology - Drug Profile 119
ET-004 - Drug Profile 120
ETX-6991 - Drug Profile 121
FIB-111 - Drug Profile 122
Gene Therapy for Age-Related Macular Degeneration - Drug Profile 123
GZ-402663 - Drug Profile 124
HB-002.1 - Drug Profile 125
HL-036 - Drug Profile 126
HLS-001 - Drug Profile 127
HMR-59 - Drug Profile 128
HuCNS-SC - Drug Profile 129
IBI-302 - Drug Profile 131
INN01-OX2 - Drug Profile 132
INV-88 - Drug Profile 133
KN-014 - Drug Profile 134
LAAMD-02 - Drug Profile 135
LAAMD-03 - Drug Profile 136
LAAMD-101 - Drug Profile 137
LHA-510 - Drug Profile 138
Lycium Anti-Angiogenic Proteoglycan - Drug Profile 139
Monoclonal Antibodies to Inhibit HTRA1 for AMD - Drug Profile 140
Monoclonal Antibody to Inhibit LRG1 for AMD - Drug Profile 141
MRZ-99030 - Drug Profile 142
NAV-2729 - Drug Profile 143
NMIL-121 - Drug Profile 145
NOP-4 - Drug Profile 147
OC-10X - Drug Profile 148
Oligonucleotide 2 for Age Related Macular Degeneration and Proliferative Vitreoretinopathy - Drug Profile 149
Oligonucleotide for Age Related Macular Degeneration and Proliferative Vitreoretinopathy - Drug Profile 150
OMS-721 - Drug Profile 151
ORA-102 - Drug Profile 153
P-17 - Drug Profile 154
P-529 - Drug Profile 156
PMX-20005 - Drug Profile 158
Polysaccharides for Age-Related Macular Degeneration - Drug Profile 159
PRCN-408 - Drug Profile 161
PRM-151 - Drug Profile 162
PRM-167 - Drug Profile 164
Protein to Inhibit Complement for Age Related Macular Degeneration - Drug Profile 165
ranibizumab - Drug Profile 166
ranibizumab biosimilar - Drug Profile 169
RTU-007 - Drug Profile 170
RX-10045 - Drug Profile 171
S-646240 - Drug Profile 173
Small Molecule for Age Related Macular Degeneration - Drug Profile 174
Small Molecule for Cancer, Inflammation and AMD - Drug Profile 175
Small Molecule for Dry Age Related Macular Degeneration - Drug Profile 176
Small Molecule to Inhibit Amyloid Beta Peptide for Age Related Macular Degeneration - Drug Profile 177
Small Molecule to Inhibit Kallikrein for AMD and DME - Drug Profile 178
Small Molecules for Age-Related Macular Degeneration - Drug Profile 179
Small Molecules for Age-Related Macular Degeneration - Drug Profile 180
Small Molecules for AMD - Drug Profile 181
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 182
Small Molecules for Ocular Diseases - Drug Profile 183
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 184
Small Molecules to Inhibit Arf6 for Multiple Diseases - Drug Profile 185
Small Molecules to Inhibit Cell Migration - Drug Profile 187
Small Molecules to Inhibit HTRA1 for AMD - Drug Profile 188
Small Molecules to Inhibit MMP - Drug Profile 189
Small Molecules to Modulate Nuclear Receptors for AMD - Drug Profile 190
Stem Cell Therapy for Age Related Macular Degeneration - Drug Profile 191
Stem Cell Therapy for Age Related Macular Degeneration - Drug Profile 192
Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile 193
Stem Cell Therapy for Macular Degeneration and Glaucoma - Drug Profile 194
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 195
Stem Cell Therapy for Ophthalmological Disorders - Drug Profile 196
Stem Cell Therapy for Parkinson Disease and Age-related Macular Degeneration - Drug Profile 197
STP-601 - Drug Profile 198
Vaccine to Target VEGFR-1 and VEGFR-2 for Ophthalmology - Drug Profile 199
VAR-10200 - Drug Profile 200
VEGF-Kinoid - Drug Profile 201
XB-2202 - Drug Profile 203
Age Related Macular Degeneration - Recent Pipeline Updates 204
Age Related Macular Degeneration - Dormant Projects 228
Age Related Macular Degeneration - Discontinued Products 233
Age Related Macular Degeneration - Product Development Milestones 234
Featured News & Press Releases 234
Appendix 245
Methodology 245
Coverage 245
Secondary Research 245
Primary Research 245
Expert Panel Validation 245
Contact Us 246
Disclaimer 246

List of Tables
Number of Products under Development for Age Related Macular Degeneration, H2 2014 18
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2014 19
Number of Products under Development by Companies, H2 2014 21
Number of Products under Development by Companies, H2 2014 (Contd..1) 22
Number of Products under Development by Companies, H2 2014 (Contd..2) 23
Number of Products under Development by Companies, H2 2014 (Contd..3) 24
Number of Products under Development by Companies, H2 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2014 27
Comparative Analysis by Clinical Stage Development, H2 2014 28
Comparative Analysis by Early Stage Development, H2 2014 29
Comparative Analysis by Unknown Stage Development, H2 2014 30
Products under Development by Companies, H2 2014 31
Products under Development by Companies, H2 2014 (Contd..1) 32
Products under Development by Companies, H2 2014 (Contd..2) 33
Products under Development by Companies, H2 2014 (Contd..3) 34
Products under Development by Companies, H2 2014 (Contd..4) 35
Products under Investigation by Universities/Institutes, H2 2014 36
Age Related Macular Degeneration - Pipeline by Advanced Cell Technology, Inc., H2 2014 37
Age Related Macular Degeneration - Pipeline by Alcon, Inc., H2 2014 38
Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2014 39
Age Related Macular Degeneration - Pipeline by Allergan, Inc., H2 2014 40
Age Related Macular Degeneration - Pipeline by AlphaMab Co., Ltd, H2 2014 41
Age Related Macular Degeneration - Pipeline by Amarna Therapeutics B.V., H2 2014 42
Age Related Macular Degeneration - Pipeline by AngioGenex, Inc., H2 2014 43
Age Related Macular Degeneration - Pipeline by Angstrom Pharmaceuticals, Inc., H2 2014 44
Age Related Macular Degeneration - Pipeline by Aprogen, Inc., H2 2014 45
Age Related Macular Degeneration - Pipeline by Auven Therapeutics Management L.L.L.P, H2 2014 46
Age Related Macular Degeneration - Pipeline by BioDiem Ltd, H2 2014 47
Age Related Macular Degeneration - Pipeline by BioMAS Ltd., H2 2014 48
Age Related Macular Degeneration - Pipeline by Cellceutix Corporation, H2 2014 49
Age Related Macular Degeneration - Pipeline by Clanotech AB, H2 2014 50
Age Related Macular Degeneration - Pipeline by Digna Biotech, S.L., H2 2014 51
Age Related Macular Degeneration - Pipeline by Dong-A Socio Group, H2 2014 52
Age Related Macular Degeneration - Pipeline by e-Therapeutics plc, H2 2014 53
Age Related Macular Degeneration - Pipeline by Eucalyptus Ltd., H2 2014 54
Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 55
Age Related Macular Degeneration - Pipeline by Gene Signal International SA, H2 2014 56
Age Related Macular Degeneration - Pipeline by Genzyme Corporation, H2 2014 57
Age Related Macular Degeneration - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 58
Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 59
Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co., Ltd., H2 2014 60
Age Related Macular Degeneration - Pipeline by Innovent Biologics, Inc., H2 2014 61
Age Related Macular Degeneration - Pipeline by Intellect Neurosciences, Inc., H2 2014 62
Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2014 63
Age Related Macular Degeneration - Pipeline by Johnson & Johnson, H2 2014 64
Age Related Macular Degeneration - Pipeline by Lead Discovery Center GmbH, H2 2014 65
Age Related Macular Degeneration - Pipeline by LeadArtis S.L., H2 2014 66
Age Related Macular Degeneration - Pipeline by Mabion SA, H2 2014 67
Age Related Macular Degeneration - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2014 68
Age Related Macular Degeneration - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 69
Age Related Macular Degeneration - Pipeline by NeoStem, Inc., H2 2014 70
Age Related Macular Degeneration - Pipeline by Neovacs SA, H2 2014 71
Age Related Macular Degeneration - Pipeline by Neumedicines Inc., H2 2014 72
Age Related Macular Degeneration - Pipeline by Neuroptis Biotech, H2 2014 73
Age Related Macular Degeneration - Pipeline by OcuCure Therapeutics, Inc., H2 2014 74
Age Related Macular Degeneration - Pipeline by Omeros Corporation, H2 2014 75
Age Related Macular Degeneration - Pipeline by Ora Bio Ltd., H2 2014 76
Age Related Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 77
Age Related Macular Degeneration - Pipeline by Promedior, Inc., H2 2014 78
Age Related Macular Degeneration - Pipeline by R-Tech Ueno, Ltd., H2 2014 79
Age Related Macular Degeneration - Pipeline by RestorGenex Corporation, H2 2014 80
Age Related Macular Degeneration - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014 81
Age Related Macular Degeneration - Pipeline by Shionogi & Co., Ltd., H2 2014 82
Age Related Macular Degeneration - Pipeline by Sirnaomics, Inc., H2 2014 83
Age Related Macular Degeneration - Pipeline by StemCells, Inc., H2 2014 84
Age Related Macular Degeneration - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 85
Age Related Macular Degeneration - Pipeline by Valens Therapeutics, Inc., H2 2014 86
Age Related Macular Degeneration - Pipeline by Varinel, Inc., H2 2014 87
Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corporation, H2 2014 88
Age Related Macular Degeneration - Pipeline by X-BODY BioSciences, Inc., H2 2014 89
Assessment by Monotherapy Products, H2 2014 90
Number of Products by Stage and Target, H2 2014 92
Number of Products by Stage and Mechanism of Action, H2 2014 95
Number of Products by Stage and Route of Administration, H2 2014 97
Number of Products by Stage and Molecule Type, H2 2014 99
Age Related Macular Degeneration Therapeutics - Recent Pipeline Updates, H2 2014 210
Age Related Macular Degeneration - Dormant Projects, H2 2014 234
Age Related Macular Degeneration - Dormant Projects (Contd..1), H2 2014 235
Age Related Macular Degeneration - Dormant Projects (Contd..2), H2 2014 236
Age Related Macular Degeneration - Dormant Projects (Contd..3), H2 2014 237
Age Related Macular Degeneration - Dormant Projects (Contd..4), H2 2014 238
Age Related Macular Degeneration - Discontinued Products, H2 2014 239